在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

Human low density lipoprotein receptor,LDLR ELISA Kit

  • 中文名稱:
    人低密度脂蛋白受體(LDLR)酶聯免疫試劑盒
  • 貨號:
    CSB-E08950h
  • 規格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人低密度脂蛋白受體(LDLR)酶聯免疫試劑盒(CSB-E08950h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的LDLR含量。LDLR(低密度脂蛋白受體)是調節膽固醇代謝的關鍵蛋白,其表達受到精確的轉錄、轉錄后和翻譯后調控。LDLR通過內吞作用清除血液中的LDL,維持膽固醇穩態。研究顯示,LDLR的表達和功能受多種因素影響,如膽固醇水平、PCSK9蛋白等,其異常與多種疾病相關。試劑盒檢測范圍為31.25 pg/mL-2000 pg/mL,靈敏度為7.8 pg/mL。本產品適用于科研領域精準檢測血清、血漿或組織勻漿樣本中LDLR的蛋白表達水平,可為心血管疾病機制研究及藥物開發提供實驗工具,適用于實驗室開展血脂調控通路研究、疾病模型構建或生物標志物篩選等科研項目。本品僅用于科研,不用于臨床診斷,產品具體參數及操作步驟詳見產品說明書。
  • 別名:
    FH ELISA Kit; FHC ELISA Kit; LDL R ELISA Kit; LDL receptor ELISA Kit; LDLCQ2 ELISA Kit; Ldlr ELISA Kit; LDLR_HUMAN ELISA Kit; Low Density Lipoprotein Receptor ELISA Kit; Low density lipoprotein receptor class A domain containing protein 3 ELISA Kit; Low density lipoprotein receptor familial hypercholesterolemia ELISA Kit; Low-density lipoprotein receptor ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    31.25 pg/mL-2000 pg/mL
  • 靈敏度:
    7.8 pg/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Cardiovascular
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

     

    Intra-Assay Precision

    Inter-Assay Precision

    Sample

    1

    2

    3

    1

    2

    3

    n

    20

    20

    20

    20

    20

    20

    Mean(pg/ml)

    223.147

    228.145

    235.557

    220.006

    229.982

    237.908

    SD

    0.038

    0.041

    0.048

    0.043

    0.051

    0.058

    CV(%)

    4.551

    4.846

    5.568

    5.193

    6

    6.69

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human LDLR in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:20

    Average %

    96

    Range %

    88-99

    1:40

    Average %

    101

    Range %

    94-105

    1:80

    Average %

    92

    Range %

    84-96

    1:160

    Average %

    104

    Range %

    94-107

  • 回收率:

    The recovery of human LDLR spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    108

    101-112

    Heparin plasma (n=4)

    94

    87-98

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    pg/ml

    OD1

    OD2

    Average

    Corrected

    2000

    2.372

    2.3

    2.336

    2.232

    1000

    1.738

    1.683

    1.711

    1.607

    500

    1.32

    1.302

    1.311

    1.207

    250

    0.818

    0.834

    0.826

    0.722

    125

    0.552

    0.543

    0.548

    0.444

    62.5

    0.327

    0.317

    0.322

    0.218

    31.25

    0.22

    0.212

    0.216

    0.112

    0

    0.103

    0.105

    0.104

  • 數據處理:
  • 貨期:
    3-5 working days

產品評價

靶點詳情

  • 功能:
    Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits.; (Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes, but not through a direct interaction with viral proteins.; (Microbial infection) Acts as a receptor for Vesicular stomatitis virus.; (Microbial infection) In case of HIV-1 infection, may function as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells.
  • 基因功能參考文獻:
    1. HepG2 cell lines transfected with siRNA directed to PCSK9 were challenged with Hcy, homocysteine thiolactone (HTL), testosterone, 5alpha-dihydroxytestosterone (5alpha-DHT), or estradiol for 24h, leading to an overt expression of PCSK9 and down-regulated expression of LDLR. PMID: 29660344
    2. A randomized trial and novel SPR technique identifies altered lipoprotein-LDL receptor binding as a mechanism underlying elevated LDL-cholesterol in APOE4s PMID: 28276521
    3. Authors performed an analysis of public databases and literature for every variant published associated with FH, in the genes LDLR, APOB, and PCSK9. PMID: 29261184
    4. In this review we present a broad spectrum of functionally characterized missense LDLr variants identified in patients with Familial hypercholesterolemia (FH), which is mandatory for a definite diagnosis of FH. PMID: 29874871
    5. The frequency of known mutations in the LDLR gene in this cohort of patients was markedly low compared to frequencies reported in other populations. PMID: 29720182
    6. This study adds 9 novel variations and 11 recurrent variations to the spectrum of LDLR gene mutations in Indian population. The in silico analysis for all the variations detected in this study were done to predict the probabilistic effect in pathogenicity of Familial Hypercholesterolemia. PMID: 29269200
    7. Data suggest maternal glycemic response during pregnancy is associated with lower DNA methylation of 4 CpG sites within PDE4B gene in placenta (collected after normal-weight term birth); 3 additional CpG sites are differentially methylated relative to maternal glucose response within TNFRSF1B, LDLR, and BLM genes. (PDE4B = phosphodiesterase-4B; TNFRSF1B = TNF receptor superfamily member-1B; BLM = Bloom syndrome protein) PMID: 29752424
    8. Vesicular stomatitis virus G protein complex with two distinct cysteine-rich domains (CR2 and CR3) of LDL-R PMID: 29531262
    9. Report familial hypercholesterolemia patients with multiple mutations at the LDLR gene presenting with more severe phenotype than single mutants. PMID: 28645073
    10. LDLr in the activated PSFs may become a novel target receptor for controlled drug delivery. PMID: 28686975
    11. Systematic mutation of the AREs (ARE1-3) in the LDLR 3'UTR and expression of each mutant coupled to a luciferase reporter in Huh7 cells demonstrated that ARE1 is required for rapid LDLR mRNA decay and 5-AzaC-induced mRNA stabilization via the IRE1alpha-EGFR-ERK1/2 signaling cascade. PMID: 29208426
    12. The genotype-risk associations were examined between LDLR (rs885765, rs688, rs5925, rs55903358, rs5742911) and obesity-related phenotypes and other comorbidities in Sucre, Venezuela. The association between LDLR rs5742911 ancestral genotype A/A and high risk condition related to HDL-cholesterol was the only one found to be significant:(A/A: 41.50+/-14.81 mg/dL; A/G: 45.00+/-12.07 mg/dL; G/G: 47.17+/-9.43 mg/dL). PMID: 27622441
    13. Heparan sulfate proteoglycans binding is required for PCSK9-induced LDLR degradation. PMID: 28894089
    14. membrane LDLR was reduced and lost the ability to take up LDL. Our data also expand the spectrum of known LDLR mutations PMID: 29228028
    15. Liposomes modified with both apolipoproteins A-I and E were internalized in HepG2 cells in FBS-depleted culture medium at the same levels as unmodified liposomes in FBS-containing culture medium, which indicates that apolipoproteins A-I and E were the major serum components involved in liposomal binding to SR-B1 or LDLR (or both). PMID: 28888368
    16. These findings suggest that LDLR rs2738464 may affect the affinity of miR-330 binding to the LDLR 3'-UTR, thus regulating LDLR expression and contributing to clear cell renal cell carcinoma risk PMID: 29029037
    17. the p.(Gly20Arg) change in the LDL receptor, previously described as disease causing, has no detrimental effect on protein expression or LDL particle binding PMID: 27175606
    18. Twenty mutations including synonymous, missense, and intronic mutations were identified in the LDLR coding region of 32 Brazilian patients with familial hypercholesterolemia. PMID: 28873201
    19. Results indicate the importance of the LDL receptor (LDLR) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C). PMID: 28759039
    20. Identify LDLR, APOB and PCSK9 novel mutations causing familial hypercholesterolemia in the central south region of China. PMID: 28235710
    21. This study updates the LDLR variant database and identifies a number of reported variants of unknown significance where additional family and in vitro studies will be required to confirm or refute their pathogenicity. PMID: 27821657
    22. Data indicate that proteasomal degradation, lysosomal degradation, autophagy or ectodomain cleavage were not the underlying mechanism for degradation of these mutant LDLRs. PMID: 28334946
    23. PCSK9 inhibits lipoprotein(a) clearance through the LDLR. PMID: 28750079
    24. 4 siblings found to be compound heterozygotes for 2 LDLR gene mutations but showing a different phenotype severity PMID: 27578127
    25. LDLR is a relevant receptor for CNS drug delivery via receptor-mediated transcytosis and that the peptide vectors we developed have the potential to transport drugs PMID: 28108572
    26. Higher Gleason grade was associated with lower LDLR expression, lower SOAT1 and higher SQLE expression. Besides high SQLE expression, cancers that became lethal despite primary treatment were characterized by low LDLR expression (odds ratio for highest versus lowest quintile, 0.37; 95% CI 0.18-0.76) and by low SOAT1 expression (odds ratio, 0.41; 95% CI 0.21-0.83). PMID: 28595267
    27. LDLR associated with Familial Hypercholesterolemia and Polygenic Hypercholesterolemia in patients with Acute Coronary Syndrome , age /=160 mg/dl. PMID: 28958330
    28. Chinese W483X mutation in the low-density lipoprotein-receptor gene in young patients with homozygous familial hypercholesterolemia PMID: 27206941
    29. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia PMID: 27206942
    30. both LDLR rs6511720 and rs57217136 are functional variants; both these minor alleles create enhancer-binding protein sites for transcription factors and may contribute to increased LDLR expression, which is consequently associated with reduced LDL-C levels and 12% lower coronary heart disease risk PMID: 27973560
    31. Using assays that measured conformational change, acid-dependent lipoprotein release, LDLR recycling, and net lipoprotein uptake, we show that H635 plays important roles in acid-dependent conformational change and lipoprotein release, while H264, H306, and H439 play ancillary roles in the response of the LDLR to acidic pH PMID: 27895090
    32. these studies support that reductions in Lp(a) with PCSK9 inhibition are partly due to increased LDLR-mediated uptake. In most situations, Lp(a) appears to compete poorly with LDL for LDLR binding and internalization, but when LDLR expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a) is reduced. PMID: 27102113
    33. Genetic etiology of familial hypercholesterolemia was confirmed in 103 probands following analysis of the whole LDLR gene in a Slovak population. PMID: 27824480
    34. Heterozygous Familial Hypercholesterolemia patients with the null low-density lipoprotein (LDL) receptor DEL15Kb mutation develop severe Aortic Calcifications in an age- and gene dosage-dependent manner. PMID: 28449836
    35. hepatocytes clear lipopolysaccharides from the circulation via the LDLR. PMID: 27171436
    36. the zymogen form of PCSK9 adopts a structure that is distinct from the processed form and is unable to bind a mimetic peptide based on the EGF-A domain of the LDLr. PMID: 27534510
    37. PCSK9 C-terminal domain (CTD) was found to be essential to induce LDLR degradation both upon its overexpression in cells or via the extracellular pathway. PMID: 27280970
    38. LDLR mutation is associated in children and adolescent with familial hypercholesterolemia. PMID: 28161202
    39. Even though LDLR-R410S and LDLR-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR-WT. PMID: 27998977
    40. study provides the first evidence that GPC3 can modulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR in HepG2 cells. PMID: 27758865
    41. ox-LDL play a role in the pathogenesis of AMD by NLRP3 inflammasome activation. Suppression of NLRP3 inflammasome activation could attenuate RPE degeneration and AMD progression. PMID: 27607416
    42. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. PMID: 27284008
    43. This study demonstrated that IL-2 and IL-10 were related to gene polymorphisms of LDL-R, which might be involved in the development and progress of hypercholesterolemia. PMID: 27121486
    44. Lipoprotein profiles get improved by liver-directed gene transfer of human LDLR gene in hypercholesterolaemia mice. PMID: 27350674
    45. Multiple novel LDLR and ApoB mutations have been identified in a-United Kingdom-based cohort with familial hypercholesterolemia. PMID: 26748104
    46. Mutations in LDLR is associated with coronary artery disease. PMID: 26927322
    47. LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele increased the risk of premature coronary artery disease by 1.8, 2.1 and 12.1 respectively. PMID: 27236033
    48. The TT genotype of rs688 in the LDLR gene was not found to be associated with elevated levels of total cholesterol or LDL-C PMID: 25601895
    49. Report increased intestinal cholesterol absorption and elevated serum cholesterol in families with primary hypercholesterolemia without mutations in LDLR. PMID: 26802983
    50. We have used atomistic simulations to explore the complete SNP mutational space (227 mutants) of the LA5 repeat, the key domain for interacting with LDL that is coded in the exon concentrating the highest number of mutations. PMID: 26755827

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Familial hypercholesterolemia (FH)
  • 亞細胞定位:
    Cell membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit. Golgi apparatus. Early endosome. Late endosome. Lysosome.
  • 蛋白家族:
    LDLR family
  • 數據庫鏈接:

    HGNC: 6547

    OMIM: 143890

    KEGG: hsa:3949

    STRING: 9606.ENSP00000454071

    UniGene: Hs.213289



主站蜘蛛池模板: 亚洲欧美日韩综合av| av一区二区三区人妻少妇| 久爱www人成免费网站| 亚洲精品av无码喷奶水网站| 久久人妻av一区二区软件| 丰满少妇人妻久久久久久| 亚洲大尺度无码无码专线| 精产国品一二三产区9977| 嫖妓大龄熟妇正在播放| 国产人碰人摸人爱免费视频| 亚洲h在线播放在线观看h| 婷婷五月俺也去人妻| 九九久re8在线精品视频| 欲香欲色天天综合和网| 国产精品人妻一码二码尿失禁| 中文字幕日韩精品亚洲一区| 亚洲精品国产美女久久久99| 亚洲中久无码永久在线观看同| 国产高潮国产高潮久久久| 午夜婷婷精品午夜无码a片影院| 欲色影视天天一区二区色香欲| 亚洲成a人片在线观看你懂的| 日韩激情无码不卡码| 无码av免费毛片一区二区| 精品亚洲成a人在线观看青青| 日本熟妇厨房bbw| 荫蒂被男人添的好舒服爽免费视频| 亚洲欧美精品suv| 日本丰满护士爆乳xxxx| 国产精品99久久久久久久女警| 十八18禁国产精品www| 永久免费无码成人网站| 中本亚洲欧美国产日韩| 久久99精品久久只有精品| 高h猛烈失禁潮喷无码视频| 偷窥村妇洗澡毛毛多| 欧美人与zoxxxx另类| 美女扒开屁股让男人桶| 亚洲乱码卡一卡二卡新区中国| 四虎成人精品永久网站| 亚洲欧洲日产国码无码久久99|